Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Cell Biochem Funct ; 42(4): e4055, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38856033

ABSTRACT

The heterogeneity of the solid tumor microenvironment (TME) impairs the therapeutic efficacy of standard therapies and also reduces the infiltration of antitumor immune cells, all of which lead to tumor progression and invasion. In addition, self-renewing cancer stem cells (CSCs) support tumor dormancy, drug resistance, and recurrence, all of which might pose challenges to the eradication of malignant tumor masses with current therapies. Natural forms of oncolytic viruses (OVs) or engineered OVs are known for their potential to directly target and kill tumor cells or indirectly eradicate tumor cells by involving antitumor immune responses, including enhancement of infiltrating antitumor immune cells, induction of immunogenic cell death, and reprogramming of cold TME to an immune-sensitive hot state. More importantly, OVs can target stemness factors that promote tumor progression, which subsequently enhances the efficacy of immunotherapies targeting solid tumors, particularly the CSC subpopulation. Herein, we describe the role of CSCs in tumor heterogeneity and resistance and then highlight the potential and remaining challenges of immunotherapies targeting CSCs. We then review the potential of OVs to improve tumor immunogenicity and target CSCs and finally summarize the challenges within the therapeutic application of OVs in preclinical and clinical trials.


Subject(s)
Immunotherapy , Neoplasms , Neoplastic Stem Cells , Oncolytic Virotherapy , Oncolytic Viruses , Humans , Neoplastic Stem Cells/immunology , Oncolytic Viruses/genetics , Oncolytic Viruses/immunology , Neoplasms/therapy , Neoplasms/immunology , Tumor Microenvironment/immunology , Animals
2.
Future Microbiol ; 16: 1415-1451, 2021 12.
Article in English | MEDLINE | ID: mdl-34812049

ABSTRACT

Emerging epidemic-prone diseases have introduced numerous health and economic challenges in recent years. Given current knowledge of COVID-19, herd immunity through vaccines alone is unlikely. In addition, vaccination of the global population is an ongoing challenge. Besides, the questions regarding the prevalence and the timing of immunization are still under investigation. Therefore, medical treatment remains essential in the management of COVID-19. Herein, recent advances from beginning observations of COVID-19 outbreak to an understanding of the essential factors contributing to the spread and transmission of COVID-19 and its treatment are reviewed. Furthermore, an in-depth discussion on the epidemiological aspects, clinical symptoms and most efficient medical treatment strategies to mitigate the mortality and spread rates of COVID-19 is presented.


Subject(s)
COVID-19 Drug Treatment , Pharmaceutical Preparations/administration & dosage , Animals , COVID-19/immunology , COVID-19/mortality , COVID-19/virology , Humans , SARS-CoV-2/genetics , SARS-CoV-2/physiology
SELECTION OF CITATIONS
SEARCH DETAIL